Intellia Therapeutics advanced its in vivo CRISPR program for hereditary angioedema, signaling potential FDA momentum after Phase 3 results. The company’s one-time lonvo-z treatment cut hereditary angioedema swelling attack rates by 87% versus placebo, with more than 60% of treated patients becoming attack-free in the study window. Intellia also described rolling submission steps toward the FDA, positioning lonvo-z as the first in vivo gene-editing medicine with a path to U.S. approval. Industry scrutiny will focus on durability of response and longer-term safety as the regulatory process ramps. The company’s update adds to the broader competitive CRISPR landscape, where differentiation increasingly hinges on clinical durability, dosing convenience, and the quality of the regulatory package.